NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03257033,Intra-arterial Gemcitabine Vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC,https://clinicaltrials.gov/study/NCT03257033,TIGeR-PaC,RECRUITING,"The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.",NO,Locally Advanced Pancreatic Cancer,DRUG: Gemcitabine|DRUG: nab-paclitaxel|DEVICE: RenovoCath,"Overall Survival, OS from time of randomization will be calculated using the Kaplan-Meier method and compared between the test and control groups using the stratified Log-Rank Test, Up to Five Years","Overall Survival for treatment received and unresected populations, The primary endpoint analysis will be repeated for the Treatment Received and Unresected Subject populations., Up to Five Years|Progression Free Survival, To compare the Progression Free Survival of intra-arterial delivery of gemcitabine using the RenovoCath™ device vs. continuation of IV gemcitabine and nab-paclitaxel following induction therapy with gemcitabine and nab-paclitaxel and radiation treatment for locally advanced pancreatic adenocarcinoma. Disease response and progression will be assessed according to RECIST 1.1., Up to Five Years|Objective response rate and duration of response, Objective response is defined as a complete response, CR, or partial response, PR, determined by Investigator assessment and confirmed by repeat assessment ≥ 4 weeks after initial documentation., Up to Five Years|Health Related Quality of Life, The EORTC questionnaire will be used to assess health related quality of life. The summary scores for the EORTC questionnaire will be calculated at baseline and follow-up., Up to Five Years|Neuropathy Assessment, The degree of neuropathy will be measured by the FACT/GOG-NTX-4 (version 4). The results will be cross tabulated by randomized treatment group for each study visit., 1 Year|Frequency of neutropenia, Neutropenia with onset after randomization requiring the use of filgrastim or other medications for white blood cell stimulation will be compared between the test and control groups through progression of disease., 1 Year|Patient reported symptoms, Symptoms reported by subjects using the PRO-CTCAE questionnaire will be compared between the test and control groups through progression of disease., Up to Five Years|Safety, defined as adverse event rate, and tolerability, defined as occurrence of treatment discontinuation, Safety and tolerability will be assessed by the occurrence of treatment discontinuation and the presence of adverse events, Up to Five Years",,RenovoRx,,ALL,"ADULT, OLDER_ADULT",PHASE3,190,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,RR3 [CP-03-001],2018-03-12,2026-06,2026-09,2017-08-22,,2024-12-09,"VA Loma Linda Healthcare System, Loma Linda, California, 92357, United States|Sutter Cancer Center Sacramento, Sacramento, California, 95816, United States|Rocky Mountain Cancer Centers, Denver, Colorado, 80218, United States|Comprehensive Cancer Care and Research Institute of Colorado, CCCRIC, Englewood, Colorado, 80113, United States|Georgetown University, Washington, District of Columbia, 20057, United States|21st Century Oncology, Fort Myers, Florida, 33907, United States|Miami Cancer Center, Miami, Florida, 33167, United States|Sarasota Memorial Health Care System, Sarasota, Florida, 34329, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|ASCLEPES Research Centers, Weeki Wachee, Florida, 34607, United States|Piedmont-Columbus Regional - John B. Amos Cancer Center, Columbus, Georgia, 31904, United States|University of Iowa Hospitals and Clinics - Holden Comprehensive Cancer Center, Iowa City, Iowa, 52242, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|LSU Health Shreveport, Shreveport, Louisiana, 71103, United States|Medstar Franklin Square, Baltimore, Maryland, 21237, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03766, United States|MD Anderson Cancer Center at Cooper Hospital, Camden, New Jersey, 08103, United States|Atlantic Health System - Morristown Medical Center, Morristown, New Jersey, 07960, United States|Albany Stratton VA Medical Center, Albany, New York, 12208, United States|Montefiore Hospital, Bronx, New York, 10461, United States|Feinstein Institutes for Medical Research - Northwell Health, Manhasset, New York, 11030, United States|Columbia University Medical Center, New York, New York, 10032, United States|Levine Cancer Institute - Atrium Health, Charlotte, North Carolina, 28204, United States|East Carolina University, Greenville, North Carolina, 27834, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, 27157, United States|Oklahoma University - Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15232, United States|Medical University of South Carolina - Hollings Cancer Center, Charleston, South Carolina, 29425, United States|Prisma Health (formerly Greenville Health System), Greenville, South Carolina, 29605, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|VA Puget Sound Health Care System, Seattle, Washington, 98108, United States|West Virginia University Medicine, Morgantown, West Virginia, 26506, United States|AZ Sint-Lucas, Brugge, 8310, Belgium|UZ Antwerp, Edegem, 2650, Belgium|AZ Maria Middelares, Gent, 9000, Belgium|UZ Gent, Gent, 9000, Belgium|Jolimont Hospital, La Louvière, 7100, Belgium|AZ Delta, Roeselare, 8800, Belgium",
